Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
Completed
- Conditions
- Epidermolysis Bullosa Dystrophica
- Registration Number
- NCT00904163
- Lead Sponsor
- Stanford University
- Brief Summary
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by the absence of type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening RDEB subjects to determine additional characteristics of patients who survive to adulthood.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
- Clinical diagnosis of RDEB by local dermatologist. 2. 18 years of age or more and willing to give consent.
Exclusion Criteria
- Medical instability limiting ability to travel to Stanford University Medical Center.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie type VII collagen deficiency in RDEB patients like those in NCT00904163?
Are there emerging therapies targeting COL7A1 mutations for RDEB beyond observational studies?
What biomarkers correlate with improved survival in adult RDEB patients from NCT00904163?
How do current wound management strategies compare for RDEB patients in clinical practice?
What adverse events are commonly reported in RDEB clinical trials and how are they managed?
Trial Locations
- Locations (1)
Stanford University School of Medicine
🇺🇸Stanford, California, United States
Stanford University School of Medicine🇺🇸Stanford, California, United States